ILLUMINA, INC. — fact timeline

ILLUMINA, INC. reported Fiscal Year 2022 results: revenue $4.58 billion, EPS $(28.00) per share.

“Revenue of $4.58 billion for fiscal year 2022, up 1% from fiscal year 2021, and up 3% on a constant currency basis • GAAP diluted loss per share of $(0.89) for Q4 2022, compared to GAAP diluted earnings per share of $0.71 for Q4 2021 • Non-GAAP diluted earnings per share of $0.14 for Q4 2022, compared to non-GAAP diluted earnings per share of $0.75 for Q4 2021 • GAAP diluted loss per share of $(28.00) for fiscal year 2022, compared to GAAP diluted earnings per share of $5.04 for fiscal year 2021, and included $(24.93) per diluted share due to goodwill impairment related to the GRAIL segment and $(0.55) per diluted share due to an increase in tax expense from R&D capitalization requirements that were not repealed in Q4 2022”

ILLUMINA, INC. reported Q4 2022 results: revenue $1.08 billion, net income $(140) million, EPS $(0.89) per share.

“+1.858.291.6421 ir@illumina.com Media: David McAlpine +1.347.327.1336 pr@illumina.com Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022 • Revenue of $1.08 billion for Q4 2022, down 10% from Q4 2021, and down 7% on a constant currency basis • Revenue of $4.58 billion for fiscal year 2022, up 1% from fiscal year 2021, and up 3% on a constant”

ILLUMINA, INC.: Amended and restated bylaws to address new universal proxy rules, including nomination procedures and proxy card color (effective 2023-02-01).

“On February 1, 2023, the Board approved an amendment and restatement of the bylaws of the Company (the “Amended and Restated Bylaws”), which became effective the same day, in order to address recently effective amendments to Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) ( i.e. , federal proxy rules regarding the use of “universal” proxy cards in contested director elections) , including by:”

Joydeep Goswami was appointed as Chief Financial Officer at ILLUMINA, INC..

“On February 1, 2023, Illumina, Inc. (the “Company”) announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer & Interim Chief Financial Officer of the Company, has been appointed as Chief Financial Officer of the Company, effective January 31, 2023 (the “Appointment Date”).”

ILLUMINA, INC. reported preliminary financial results for fourth quarter and fiscal year ended January 1, 2023.

“On January 9, 2023, Illumina, Inc. (the "Company"), presented at the J.P. Morgan Healthcare Conference in San Francisco, California during which it discussed preliminary financial results for the fourth quarter and fiscal year ended January 1, 2023.”

ILLUMINA, INC. incurred revolving credit of $750 million with Bank of America, N.A. and other lenders maturing January 4, 2028.

“The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility (with a $40 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit) (the "Credit Facility").”

ILLUMINA, INC. terminated Existing Credit Agreement with Bank of America, N.A., as administrative agent, an issuing bank and the swingline lender (effective 2023-01-04).

“(“Illumina” or the “Company”) entered into a credit agreement (the “Credit Agreement”) among the Company, as the borrower, the lenders from time to time party thereto, Bank of America, N.A., as administrative agent, an issuing bank and the swingline lender, and the other issuing banks from time to time party thereto.”

ILLUMINA, INC. entered into Credit Agreement with Bank of America, N.A., as administrative agent, an issuing bank and the swingline lender valued at $750 million (effective 2023-01-04).

“On January 4, 2023, Illumina, Inc. (“Illumina” or the “Company”) entered into a credit agreement (the “Credit Agreement”) among the Company, as the borrower, the lenders from time to time party thereto, Bank of America, N.A., as administrative agent, an issuing bank and the swingline lender, and the other issuing banks from time to time party thereto.”

ILLUMINA, INC. reported third quarter ended October 2, 2022 results: revenue $1.12 billion, net income $ (3,816), EPS $(24.26). Guidance initiated.

“Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022 • Revenue of $1.12 billion for Q3 2022, up 1% from Q3 2021, and up 3% on a constant currency basis • GAAP diluted loss per share of $(24.26) for Q3 2022, compared to GAAP diluted earnings per share of $2.08 for Q3 2021; GAAP diluted loss per share for Q3 2022 includes goodwill impairment of $3.91 billion related to the GRAIL segment • Non-GAAP diluted earnings per share of $0.34 for Q3 2022, compared to non-GAAP diluted earnings per share of $1.45 for Q3 2021 • Expect full year revenue for fiscal year 2022 to be flat to 1% higher compared to fiscal year 2021, primarily reflecting year-to-date growth in sequencing consumables revenue, largely offset by a fourth quarter decline in select research project sample volume; delayed purchases ahead of the upcoming availability of NovaSeq X and from customer inventory and capital management; and incremental foreign exchange headwinds • Expect GAAP diluted loss per share of”

Scott Ericksen was appointed as Vice President and Chief Accounting Officer at ILLUMINA, INC..

“On September 29, 2022 Illumina, Inc. (the “Company”) appointed Scott Ericksen as Vice President and Chief Accounting Officer, effective as of October 16, 2022.”

Jose Torres departed as Vice President and Chief Accounting Officer at ILLUMINA, INC..

“On September 14, 2022, Jose Torres, Vice President and Chief Accounting Officer, notified Illumina, Inc. (the “Company”) that he will be leaving the Company effective as of October 14, 2022.”

Sam Samad resigned as Chief Financial Officer at ILLUMINA, INC..

“On June 8, 2022, Sam Samad, Chief Financial Officer, notified Illumina, Inc. (the “Company”) that he will be leaving the Company effective as of July 8, 2022.”